Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations.

"Disclosure Anna Vaynrub and Max Vaynrub report no conflicts of interest in this work. John Healey has served as a consultant for Daiichi Sankyo and Stryker Consultant, as a trustee for the Musculoskeletal Transplant Foundation, and as a symposium editor for Clinical Orthopaedics and Related Research. William Tap reports personal fees from Eli Lilly, EMD Serono, Mundipharma, C4 Therapeutics, Daiichi Sankyo, Blueprint, Agios Pharmaceuticals, NanoCarrier, Deciphera, Adcendo, Ayala Pharmaceuticals, Kowa, Servier, Bayer Pharmaceuticals, Epizyme, Cogent, and Medpacto outside the current article. In addition, Dr. Tap has a patent (Companion diagnostic for CDK4 inhibitors - 14/854,329) pending to Memorial Sloan Kettering Cancer Center/Sloan Kettering Institute (SKCC/SKI), and a patent (Enigma and CDH18 as companion diagnostics for CDK4 inhibition – SKI2016-021-03) pending to MSKCC/SKI; is a member of the scientific advisory boards of Certis Oncology Solutions and Innova Therapeutics, and owns stock in Atropos Therapeutics and Innova Therapeutics."

"This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748."